Plain-English translation of NCT04804241 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help slow memory loss and thinking problems in people with mild cognitive impairment or early Alzheimer's disease. About 55 people will take either or a placebo (a dummy pill with no active ingredient) for one year. The study will measure whether the medication affects how quickly thinking abilities decline and will look at markers of brain inflammation in blood and spinal fluid.
Current treatments for Alzheimer's disease have limited benefits, and researchers are looking for new approaches that might slow the disease earlier, when symptoms are mild. This medication works on a different target in the brain than existing treatments, so this study aims to understand whether it could help protect thinking ability in people in the earliest stages of cognitive decline.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the research center multiple times over 78 weeks. You'll take a daily pill (either the medication or placebo) for 52 weeks, then stop and return for one more visit 26 weeks later. You'll have brain imaging scans (MRI and possibly a PET scan), provide blood and spinal fluid samples, have your thinking abilities tested, and attend safety check-ups about every 6–8 weeks. You'll also participate in special brain activity tests called ERP studies.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States